The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
ras Mutations Are Associated With Aggressive Tumor Phenotypes and Poor Prognosis in Thyroid Cancer
Abstract
Purpose: ras oncogenic activation has long been demonstrated in thyroid carcinomas of follicular cell derivation, but no consistent relationship has been shown between mutations and clinicopathologic features. Materials and Methods: We analyzed H-, K-, and N-ras mutations by polymerase chain reaction–single-strand conformational polymorphism followed by DNA sequencing in 125 thyroid carcinoma specimens from 107 patients, to include tumors covering the entire spectrum of thyroid tumor differentiation. Results: Mutations were identified in four (8.2%) of 49 well-differentiated carcinomas (WDCs; two [6.7%] of 30 of the tumors were papillary carcinomas, two [10.5%] of 19 of them were follicular carcinomas), in 16 (55.2%) of 29 poorly differentiated carcinomas (PDCs), and in 15 (51.7%) of 29 undifferentiated carcinomas, with a significant association between ras mutation and poorly or undifferentiated tumors (P < .001). Twenty-six (74.3%) of 35 patients with ras-mutated tumors died as a result of disease as opposed to 23 (31.9%) of 72 patients with tumors lacking the mutations. Among patients with differentiated thyroid carcinomas (WDC and PDC), 11 (55.0%) of 20 patients with mutated tumors died as a result of disease as opposed to nine (15.5%) of 58 patients with wild-type ras tumors, and the correlation was independent of tumor differentiation and stage (P = .016). K-ras codon 13 mutations (all with G-A nucleotide transitions resulting in Gly>Asp substitution) and single activating mutations in any of the ras genes were also independent predictors of poor survival in differentiated thyroid carcinomas (P = .027 and P = .007, respectively). Conclusion: These findings demonstrate that ras mutations are a marker for aggressive cancer behavior and indicate a possible role of ras genotyping to identify thyroid carcinoma subsets associated with poor prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study
Andreyev, H. J. N., Norman, A. R., Cunningham, D., Oates, J., Dix, B. R., Iacopetta, B. J., Young, J., Walsh, T., Ward, R., Hawkins, N., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1964 · Cited by 872
Self-citationPrognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., et al. (1999) · PubMed · doi:10.1182/blood.v93.9.3074 · Cited by 757
Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748
Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development
Rowinsky, E. K., Windle, J. J., & Von Hoff, D. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3631 · Cited by 537
Carcangiu, M. L., Zamp, G., & Rosai, J. (1984) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198409000-00005 · Cited by 470
Self-citationPoorly Differentiated Insular Thyroid Carcinoma
Kuhel, W. I., Kutler, D. I., & Santos-Buch, C. A. (1998) · Acta Cytologica · doi:10.1159/000331983 · Cited by 401
β-Catenin Dysregulation in Thyroid Neoplasms
Garcia-Rostan, G., Camp, R. L., Herrero, A., Carcangiu, M. L., Rimm, D. L., & Tallini, G. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64045-x · Cited by 277
Self-citationActivated ras oncogenes in human thyroid cancers.
Lemoine, N. R., Mayall, E. S., Wyllie, F. S., Farr, C. J., Hughes, D., Padua, R. A., Thurston, V., Williams, E. D., & Wynford‐Thomas, D. (1988) · PubMed · Cited by 233
Implications and Prognostic Value of K-ras Mutation for Early-Stage Lung Cancer in Women
Nelson, H. H., Christiani, D. C., Mark, E. J., Wiencke, J. K., Wain, J. C., & Kelsey, K. T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.23.2032 · Cited by 227
Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors.
Capella, G., Cronauer-Mitra, S., Pienado, M. A., & Perucho, M. (1991) · Environmental Health Perspectives · doi:10.1289/ehp.9193125 · Cited by 214
Kwiatkowski, D. J., Harpole, D. H., Godleski, J., Herndon, J. E., Shieh, D. B., Richards, W., Blanco, R., Xu, H. J., Strauss, G. M., & Sugarbaker, D. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2468 · Cited by 178
Solakoglu, O., Maierhofer, C., Lahr, G., Breit, E., Scheunemann, P., Heumos, I., Pichlmeier, U., Schlimok, G., Oberneder, R., Köllermann, M. W., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.042372199 · Cited by 166
Kawesha, A., Ghaneh, P., Andrén‐Sandberg, Å., Ögraed, D., Skar, R., Dawiskiba, S., Evans, J. D., Campbell, F., Lemoine, N. R., & Neoptolemos, J. P. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001120)89:6<469::aid-ijc1>3.0.co;2-l · Cited by 152
Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas
Manenti, G., Pilotti, S., Re, F. C., Porta, G., & Pierotti, M. A. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90130-9 · Cited by 126
N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma.
Hara, H., Fulton, N. C., YASHIRO, T., Ito, K., DeGroot, L. J., & Kaplan, E. L. (1994) · PubMed · Cited by 124
Prevalence of Activating ras Mutations in Morphologically Characterized Thyroid Nodules
Ezzat, S., Zheng, L., KOLENDA, J., SAFARIAN, A., Freeman, J. L., & Asa, S. L. (1996) · Thyroid · doi:10.1089/thy.1996.6.409 · Cited by 98
The Type of K-ras Mutation Determines Prognosis in Colorectal Cancer
Cerottini, J., Caplin, S., Saraga, E. P., Givel, J., & Benhattar, J. (1998) · The American Journal of Surgery · doi:10.1016/s0002-9610(97)00283-3 · Cited by 92
Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells.
Yeung, S. J., Xu, G., Pan, J., Christgen, M., & Bamiagis, A. (2000) · PubMed · Cited by 92
Pattern of ras and gsp oncogene mutations in radiation-associated human thyroid tumors.
Vathaire, C. C.-D., Bounacer, A., Villard, J. A. D., Caillou, B., de Vathaire, F., Monier, R., Schlumberger, M. J., & Suarez, H. G. (1995) · PubMed · Cited by 69
Trimodality treatment in Stage III nonsmall cell lung carcinoma
Broermann, P., Junker, K., Brandt, B., et al. (2002) · Cancer · doi:10.1002/cncr.10387 · Cited by 54
Cited by
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
Molecular genetics and diagnosis of thyroid cancer
Nikiforov, Y. E., & Nikiforova, M. N. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.142 · Cited by 1,011
Xing, M. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0007 · Cited by 983
Ras in Cancer and Developmental Diseases
Fernandez-Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 897
Pathogenetic mechanisms in thyroid follicular-cell neoplasia
Kondo, T., Ezzat, S., & Asa, S. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1836 · Cited by 893
Metadata
- Authors
- Garcia-Rostan, G., Zhao, H., Camp, R. L., Pollan, M., Herrero, A., Pardo, J., Wu, R., Carcangiu, M. L., Costa, J., & Tallini, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-09-01
- Volume
- 21
- Issue
- 17
- Pages
- 3226-3235
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2145455579
- Cited by
- 368
- References
- 21
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.